Back to Trials
NCT06793982PHASE4Recruiting

Platelet Rich Plasma Versus Corticosteroids in Hip Osteoarthritis Pain

LifeBridge Health

Start Date

2/21/2024

Completion Date

12/1/2025

Summary

Prospective, single-center that may go on to being multicenter, randomized trial comparing platelet rich plasma (PRP) versus corticosteroid injection for the treatment of symptoms of Hip osteoarthritis. The purpose of the study is to determine which therapy provides a greater reduction in patient reported outcome measures of pain and function.

Detailed Description

Platelet rich plasma has become increasingly utilized as a treatment option for Hip osteoarthritis. Corticosteroids is currently an approved medication to treat the symptoms of the Hip osteoarthritis. There is limited evidence in a prospective randomized manner powered adequately to determine a difference between these treatments for pain associated with Hip osteoarthritis. Prospective, single center that may go on to be multi-center, single blind (participant), randomized trial comparing platelet rich plasma (PRP) versus corticosteroid injection for the treatment of symptoms of Hip osteoarthritis. The purpose of the study is to determine which therapy provides a greater reduction in patient reported outcome measures of pain and function.

Eligibility Criteria

Age Range: 21 years to 80 years

Inclusion Criteria: * Provision of signed and dated informed consent form * Stated willingness to comply with all study procedures and availability for the duration of the study * Male or female, aged 21-80 years * Radiographic diagnosis of Kellgren-Lawrence (KL) grade of II or III Hip osteoarthritis * Indicated for a Hip injection to treat Hip OA symptoms Exclusion Criteria: * Any injections into the target Hip within three months * Current overlying skin infection * Current or previous diagnosis of "chronic pain" * Opioid tolerant at time of screening (for a week or longer, at least 60 mg of morphine daily, or at least 30 mg of oral oxycodone daily, or at least 8 mg of oral hydromorphone daily or an equianalgesic dose of another opioid.) * Allergy to any potential ingredients or medications utilized in any of the two groups * Treatment with another investigational drug or other intervention for pain * Diagnosis of Diabetes Mellitus * If female, pregnant or planning to be pregnant within the following 3 months or study duration * Any condition(s) or diagnosis, both physical or psychological, or physical exam finding in the opinion of the investigator that would precludes participation

Interventions

DEVICE

Platelet Rich Plasma Joint Injection

DRUG

Corticosteroid Injection

Interested in This Trial?

Contact the trial locations directly using the information below to learn more about enrollment.

Expressing interest lets you review the study and consent before we connect you with the research site.

Conditions

Hip Osteoarthritis

Locations

Sinai Hospital of Baltimore

Baltimore, Maryland 21215

United States